✦ LIBER ✦

The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis

✍ Scribed by Edwards, Christopher J. ;Cooper, Cyrus ;Fisher, David ;Field, Max ;van Staa, Tjeerd P. ;Arden, Nigel K.

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 101 KB
Volume: 57
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.23003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The early use of disease-modifying antir

The early use of disease-modifying antirheumatic drugs in rheumatoid arthritis

✍ Edward S. Mongan 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

Use of nonbiologic disease-modifying ant

Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis

✍ Lacaille, Diane ;Guh, Daphne P. ;Abrahamowicz, Michal ;Anis, Aslam H. ;Esdaile, 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

Changes in cotherapies after initiation

Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis

✍ Vivian K. Kawai; Carlos G. Grijalva; Patrick G. Arbogast; Jeffrey R. Curtis; Dan 📂 Article 📅 2011 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 392 KB 👁 2 views

Is the outcome of rheumatoid arthritis c

Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?

✍ Kremer, Joel 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB 👁 1 views

Interleukin-6 receptor inhibition with t

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

✍ Mark C. Genovese; James D. McKay; Evgeny L. Nasonov; Eduardo F. Mysler; Nilzio A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

Five-year followup of rheumatoid arthrit

Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year

✍ Suzan M. M. Verstappen; Johannes W. G. Jacobs; Johannes W. J. Bijlsma; Anton H. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract ## Objective To evaluate whether the clinical advantages observed after 1 year in a randomized controlled clinical trial, in which 2 treatment strategies were compared (the early disease‐modifying antirheumatic drug [DMARD] approach versus the pyramid approach), persist after 5 years.